Role of the receptor for advanced glycation end products (RAGE) and its ligands in human reproduction


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Studying the components of the immune system in reproductive disorders allows a better understanding of the causes of infertility, in vitro fertilization (IVF) failure, pregnancy complications, and adverse perinatal outcomes. RAGE (receptor for advanced glycation end products) and its ligands are one of the important components of innate and adaptive immunity. This receptor is largely expressed on the membranes of alveolocytes, myocytes, endotheliocytes, immune and embryonic cells, and glial cells. High RAGE expression is associated with a variety of diseases, the pathogenesis of which is dominated by chronic stress, inflammation, or necrosis, such as diabetes mellitus, rheumatoid arthritis, and hypertension. The review analyzes data on changes in RAGE and its ligands in female and male infertility, polycystic ovary syndrome, and obesity. The paper gives clinical and fundamental studies on the levels of sRAGE in patients with diminished ovarian reserve in IVF programs and considers its possible role in the pathogenesis of reproductive aging. It also discusses in detail the role of RAGE and its main ligands during uncomplicated pregnancy, its dynamic changes in the trimester of pregnancy, and its relationship to the development of “the great obstetric syndromes”, such as threatened miscarriage and preeclampsia. Special attention is paid to the role of this receptor and its ligands in the pathogenesis of perinatal pathology in newborns, and new methods of antenatal prediction of perinatal hypoxic damage to the central nervous system are proposed. Studying RAGE and its ligands may open up new possibilities for the therapeutic use of sRAGE to prevent the damaging effects of glycation products.

Full Text

Restricted Access

About the authors

Anastasiia V. Smirnova

Ivanovo State Medical University, Ministry of Health of Russia; V.N. Gorodkov Ivanovo Research Institute of Maternity and Childhood, Ministry of Health of Russia

Email: anguseva@yandex.ru
k. m. n., docent of Department obstetrics and gynecology, medical genetics

Nadezhda Yu. Borzova

V.N. Gorodkov Ivanovo Research Institute of Maternity and Childhood, Ministry of Health of Russia

Email: borzova__n@mail.ru
MD, PhD, Dr. Med. Sci., main scientist, Department of obstetrics and gynecology

Anna I. Malyshkina

Ivanovo State Medical University, Ministry of Health of Russia; V.N. Gorodkov Ivanovo Research Institute of Maternity and Childhood, Ministry of Health of Russia

MD, PhD, Dr. Med. Sci., director

Natalia Yu. Sotnikova

Ivanovo State Medical University, Ministry of Health of Russia; V.N. Gorodkov Ivanovo Research Institute of Maternity and Childhood, Ministry of Health of Russia

Email: niimid.immune@mail.ru
MD, PhD, Dr. Med. Sci., Head of laboratory of clinical immunology

References

  1. Sparvero L.J., Asafu-Adjei D., Kang R., Tang D., Amin N., Im J. et al. RAGE (receptor for advanced glycation end products), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med. 2009; 7: 17. https://dx.doi. org/10.1186/1479-5876-7-17.
  2. Заводчик И.Б., Дремза И.К., Лапшина Е.А., Чещевик В.Т. Сахарный диабет: метаболические эффекты и окислительный стресс. Биологические мембраны. 2011; 28(2): 83-94.
  3. Buhimschi C.S., Baumbusch M.A., Dulay A.T., Oliver E.A., Lee S., Zhao G. et al. Characterization of RAGE, HMGB1, and S100beta in inflammation-induced preterm birth and fetal tissue injury. Am. J. Pathol. 2009; 175(3): 958-75. https:// dx.doi.org/10.2353/ajpath.2009.090156.
  4. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factoramplifying immune and inflammatory responses. J. Clin. Invest. 2001; 108(7): 949-55. https://dx.doi.org/10.1172/ JCI14002.
  5. Galichet A., Weibel M., Heizmann C.W. Calcium_regulated intramembrane proteolysis of the RAGE receptor. Biochem. Biophys. Res. Commun. 2008; 370(1): 1-5. https://dx.doi.org/10.1016/j.bbrc.2008.02.163.
  6. Соболева А.Г., Брускин С.А., Николаев А.А., Соболев В.В., Мезенцев А.В. Роль рецептора продуктов неферментативного гликозилирования в патогенезе псориаза. Молекулярная биология. 2013; 47(5): 743-53. https://dx.doi.org/10.7868/ S0026898413050194.
  7. Al_Hazmi N., Thomas G.J., Speight P.M., Whawell S.A. The 120 kDacell_binding fragment of fibronectin up-regulates migration of alphavbeta6-expressing cells byincreasing matrix metalloproteinase-2 and -9 secretion. Eur. J. Oral Sci. 2007; 115(6): 454-8. https://dx.doi.org/10.1111/j.1600-0722.2007.00481.x.
  8. Кузник Б.И., Хавинсон В.Х., Линькова Н.С., Салль Т.С. Алармин 1 (HMGB1) и возрастная патология. Эпигенетические механизмы регуляции. Успехи физиологических наук. 2017; 48(4): 40-5.
  9. Saha A., Kim S.J., Zhang Z., Lee Y.C., Sarkar C., Tsai P.C., Mukherjee A.B. RAGE signaling contributes to neuroinflamation in infantile neuronal ceroid lipofuscinosis. FEBS Lett. 2008; 582(27): 3823-31. https://dx.doi.org/10.1016/j. febslet.2008.10.015.
  10. Noguchi T., Sado T., Naruse K., Shigetomi H., Onogi A., Haruta S. et al. Evidence for activation of Toll-like receptor for advanced glycation end products in preterm. Mediators Inflamm. 2010; 2010: 490406. https://dx.doi. org/10.1155/2010/490406.
  11. Germanova A., Koucky M., Hajek Z., Parizek A., Zima T., Kalousova M. Soluble receptor for advanced glycation end products in physiological and pathological pregnancy. Clin. Biochem. 2010; 43(4-5): 442-6. https://dx.doi.org/10.1016/j. clinbiochem.2009.11.002.
  12. Xie L.J., Li H.J., Zhu J.X. Relationship between serum S100B protein level and brain damage in preterm infants. Zhongguo Dang Dai Er Ke Za Zhi. 2012; 14(7): 485-8.
  13. Naruse K.I., Sado T., Noguchi T., Tsunemi T., Yoshida S., Akasaka J. et al. Peripheral RAGE (receptor for advanced glycationendproducts)-ligands in normal pregnancy and preeclampsia: novel markers of inflammatory response. J. Reprod. Immunol. 2012; 93(2): 69-74. https://dx.doi.org/10.1016/j. jri.2011.12.003.
  14. Charalampidou S., Simitsopoulou M., Skoura L., Tziomalos K., Koulourida V., Goulis D.G. Soluble receptor for advanced glycation end products in male infertility. Hippokratia. 2017; 21(1): 19-24.
  15. Rutkowska A.Z., Diamanti-Kandarakis E. Do advanced glycation end products (AGEs) contribute to the comorbidities of polycystic ovary syndrome (PCOS)? Curr. Pharm. Des. 2016; 22(36): 5558-71. https://dx.doi.org/10.2174/13816128 22666160714094404.
  16. Pertynska-Marczewska M., Diamanti-Kandarakis E. Aging ovary and the role for advanced glycation end products. Menopause. 2017; 24(3): 345-51. https:// dx.doi.org/10.1097/GME.0000000000000755.
  17. Pertynska-Marczewska M., Cypryk K. The possible impact of advanced glycation end products on pregnancy outcome in women with diabetes mellitus type 1. Minerva Endocrinol. 2017; 42(3): 271-9. https://dx.doi.org/10.23736/S0391-1977.16.02477-9.
  18. Antoniotti G.S., Coughlan M., Salamonsen L.A., Evans J. Obesity associated advanced glycation end products within the human uterine cavity adversely impact endometrial function and embryo implantation competence. Hum. Reprod. 2018; 33(4): 654-65. https://dx.doi.org/10.1093/humrep/dey029.
  19. Li Y.J., Chen J.H., Sun P., Li J.J., Liang X. Y. Intrafollicular soluble RAGE benefits embryo development and predicts clinical pregnancy in infertile patients of advanced maternal age undergoing in vitro fertilization. J. Huazhong Univ. Sci. Technol. Med. Sci. 2017; 37(2): 243-7. https://dx.doi.org/10.1007/s11596-017-1722-z.
  20. Красильникова А.К., Малышкина А.И., Сотникова Н.Ю., Анциферова Ю.С., Романова С.В. Использование иммуномодулирующей терапии у женщин с бесплодием при «малых» формах наружного генитального эндометриоза. Российский вестник акушера-гинеколога. 2014; 14(3): 25-8.
  21. Sethi S., Chakraborty T. Role of TLR-/NLR-signaling and the associated cytokines involved in recruitment of neutrophils in murine models of Staphylococcus aureus infection. Virulence. 2011; 2(4): 316-28. https://dx.doi. org/10.4161/viru.2.4.16142.
  22. Ota K., Yamagishi S., Kim M., Dambaeva S., Gilman-Sachs A., Beaman K. et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in recurrent pregnancy losses (RPL): possible participation of RAGE in RPL. Fertil. Steril. 2014; 102(3): 782-9. https://dx.doi.org/10.1016/j. fertnstert.2014.06.010.
  23. Quintanilla-Garcia C.V., Uribarri J., Fajardo-Araujo M.E., Barrientos-Romero J.J., Romero-Gutierrez G., Reynaga-Ornelas M.G., Garay-Sevilla M.E. Changes in circulating levels of carboxymethyllysine, soluble receptor for advanced glycation end products (sRAGE), and inflammation markers in women during normal pregnancy. J. Matern. Fetal Neonatal Med. 2019; 32(24): 4102-7. https://dx.doi.org/10.1080/14767058.2018.1481948.
  24. Hajek Z., Germanova A., Koucky M., Zima T., Kopecky P., Vitkova M. et al. Detection of feto-maternal infection/inflammation by the soluble receptor for advanced glycation end products (sRAGE): results of a pilot study. J. Perinat. Med. 2008; 36(5): 399-404. https://dx.doi.org/10.1515/JPM.2008.080.
  25. Смирнова А.В., Борзова Н.Ю., Сотникова Н.Ю., Малышкина А.И. Клиникоиммунологические факторы риска очень ранних преждевременных родов. Проблемы репродукции. 2020; 26(2): 113-9.
  26. Смирнова А.В., Борзова Н.Ю., Сотникова Н.Ю., Малышкина А.И. Особенности содержания растворимой формы рецептора для конечных продуктов гликозилирования при очень ранних угрожающих преждевременных. Акушерство и гинекология. 2017; 10: 35-9. https:// dx.doi.org/10.18565/aig.2017.10.35-39.
  27. Колобова А.В. Особенности содержания растворимой формы рецептора для конечных продуктов гликозилирования и белка S100B при невынашивании беременности. Российский иммунологический журнал. 2012; 6(2-1): 79.
  28. Malyshkina A., Kolobova A., Sotnicova N., Borzova N. The content of SRAGE and S100 B. protein in serum of women with uncomplicated and complicated by threatening preterm labor pregnancy. J. Perinat. Med. 2013; 41: 767.
  29. Rzepka R., Dofygowska B., Rajewska A., Salata D., Budkowska M., Kwiatkowski S., Torbe A. Diagnostic potential of evaluation of SDF-1a and sRAGE levels in threatened premature labor. Biomed. Res. Int. 2016; 2016: 2719460. https:// dx.doi.org/10.1155/2016/2719460.
  30. Yan H., Zhu L., Zhang Z., Li H., Li P., Wang Y., Leng M. HMGB1-RAGE signaling pathway in pPROM.Taiwan. J. Obstet. Gynecol. 2018; 57(2): 211-6. https://dx.doi.org/10.1016/j.tjog.2018.02.008.
  31. Hannan N.J., Jones R.L., White C.A., Salamonsen L.A. The chemokines, CX3CL1, CCL14, and CCL4, promote human trophoblast migration at the feto-maternal interface. Biol. Reprod. 2006; 74(5): 896-904.
  32. Zenerino C., Nuzzo A.M., Giuffrida D., Biolcati M., Zicari A., Todros T., Rolfo A. The HMGB1/RAGE pro-inflammatory axis in the human placenta: modulating effect of low molecular weight heparin. Molecules. 2017; 22(11). pii: E1997. https://dx.doi.org/10.3390/molecules22111997.
  33. Chen W., Zhang Y., Yue C., Ye Y., Chen P., Peng W. et al. Accumulation of advanced glycation end products involved in inflammation and contributing to severe preeclampsia, in maternal blood, umbilical blood and placental tissues. Gynecol. Obstet. Invest. 2017; 82(4): 388-97. https://dx.doi.org/10.1159/000448141.
  34. Alexander K.L., Mejia C.A., Jordan C., Nelson M.B., Howell B.M., Jones C.M. et al. Differential receptor for advanced glycation end products expression in preeclamptic, intrauterine growth restricted, and gestational diabetic placentas. Am. J. Reprod. Immunol. 2016; 75(2): 172-80. https://dx.doi.org/10.1111/ aji.12462.
  35. Линде В.А., Палиева Н.В., Боташева Т.Л., Авруцкая В.В., Дударева М.В. Роль про- и контринсулярных факторов в формировании акушерской патологии. Акушерство и гинекология. 2017; 2: 32-8. https://dx.doi.org/10.18565/ aig.2017.2.32-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies